AI designed lung drug shows signs of reversing biological age markers

Blood samples from a clinical trial for lung disease drug rentosertib were evaluated using six proteomic aging clocks. Results showed that participants taking the AI designed medication lowered their biological age estimates by three to six years depending on the measurement system used.